Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Michels

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Ophthalmology|October 10, 2006
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical studyAndrew A Moshfeghi, Philip J Rosenfeld, Carmen A Puliafito, et al.
The British Journal of Ophthalmology|June 23, 2018
Microvascular abnormalities secondary to radiation therapy in neovascular age-related macular degeneration: findings from the INTREPID clinical trialFlorentina Joyce Freiberg, Stephan Michels, Alyson Muldrew, et al.
Acta Ophthalmologica|December 24, 2010
Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injectionsCarsten H Meyer, Stephan Michels, Eduardo B Rodrigues, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|June 28, 2016
The Role of Anti-VEGF Therapy in the Treatment of Diabetic Macular EdemaDarius M Moshfeghi, Peter K Kaiser, Stephan Michels, et al.
Investigative Ophthalmology & Visual Science|February 2, 2011
Genetic association with response to intravitreal ranibizumab in patients with neovascular AMDBarbara Kloeckener-Gruissem, Daniel Barthelmes, Stephan Labs, et al.
Ophthalmology. Retina|May 11, 2025
Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase 3 Trials in Neovascular Age-Related Macular DegenerationNikolas J S London, Chui Ming Gemmy Cheung, Stephan Michels, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|September 30, 2010
Incidence of damage to the crystalline lens during intravitreal injectionsCarsten H Meyer, Eduardo B Rodrigues, Stephan Michels, et al.
Acta Ophthalmologica|May 6, 2025
Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen (TOLERANT study)-A non-inferiority, randomized controlled trialDamian Jaggi, Lieselotte E Berger, Sandrine Zweifel, et al.
Investigative Ophthalmology & Visual Science|August 27, 2005
Three-dimensional ultrahigh-resolution optical coherence tomography of macular diseasesUrsula Schmidt-Erfurth, Rainer A Leitgeb, Stephan Michels, et al.
International Journal of Cardiology|April 9, 2013
Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safetyStephan Winnik, Christine Lohmann, Giovanni Siciliani, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Ophthalmology|October 10, 2006
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical studyAndrew A Moshfeghi, Philip J Rosenfeld, Carmen A Puliafito, et al.
The British Journal of Ophthalmology|June 23, 2018
Microvascular abnormalities secondary to radiation therapy in neovascular age-related macular degeneration: findings from the INTREPID clinical trialFlorentina Joyce Freiberg, Stephan Michels, Alyson Muldrew, et al.
Acta Ophthalmologica|December 24, 2010
Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injectionsCarsten H Meyer, Stephan Michels, Eduardo B Rodrigues, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|June 28, 2016
The Role of Anti-VEGF Therapy in the Treatment of Diabetic Macular EdemaDarius M Moshfeghi, Peter K Kaiser, Stephan Michels, et al.
Investigative Ophthalmology & Visual Science|February 2, 2011
Genetic association with response to intravitreal ranibizumab in patients with neovascular AMDBarbara Kloeckener-Gruissem, Daniel Barthelmes, Stephan Labs, et al.
Ophthalmology. Retina|May 11, 2025
Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase 3 Trials in Neovascular Age-Related Macular DegenerationNikolas J S London, Chui Ming Gemmy Cheung, Stephan Michels, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|September 30, 2010
Incidence of damage to the crystalline lens during intravitreal injectionsCarsten H Meyer, Eduardo B Rodrigues, Stephan Michels, et al.
Acta Ophthalmologica|May 6, 2025
Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen (TOLERANT study)-A non-inferiority, randomized controlled trialDamian Jaggi, Lieselotte E Berger, Sandrine Zweifel, et al.
Investigative Ophthalmology & Visual Science|August 27, 2005
Three-dimensional ultrahigh-resolution optical coherence tomography of macular diseasesUrsula Schmidt-Erfurth, Rainer A Leitgeb, Stephan Michels, et al.
International Journal of Cardiology|April 9, 2013
Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safetyStephan Winnik, Christine Lohmann, Giovanni Siciliani, et al.
Pageof 8